Abstract: Described herein are engineered antibody constant domain molecules, such as CH2 or CH3 domain molecules, comprising at least one mutation, or comprising at least one complementarity determining region (CDR), or a functional fragment thereof, engrafted in a loop region of the CH2 domain. The CH2 domain molecules described herein are small, stable, soluble, exhibit little to no toxicity and are capable of binding antigen.
Type:
Grant
Filed:
October 1, 2013
Date of Patent:
December 27, 2016
Assignee:
The United States of America, as represent by the Secretary, Department of Health and Human Services